Journal Options Hepatitis
Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
Featured Expert Commentary
Tarek Hassanein, MD, FACP, FACG, AGAF
Professor of Medicine
Department of Medicine
University of California, San Diego
San Diego, California
Director, Clinical Trials Center
Southern California Liver & GI Centers
Coronado, California
Recent Articles
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients.
Angelico F, Franicoso S, Del Ben M, et al. Aliment Pharmacol Ther. 2009;30:444-451. Capsule Summary | Expert Commentary | Abstract | Slides
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
Berg T, Weich V, Teuber G, et al. Hepatology. 2009;50:369-377. Capsule Summary | Expert Commentary | Abstract | Slides
Early HBeAg loss during peginterferon alfa-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients.
Buster EH, Flink HJ, Simsek H, et al. Am J Gastroenterol. 2009;104:2449-2457. Capsule Summary | Expert Commentary | Abstract | Slides
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Ge D, Fellay J, Thompson AJ, et al. Nature. 2009;461:399-401. Capsule Summary | Expert Commentary | Abstract | Slides
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. N Engl J Med. 2009;361:580-593. Capsule Summary | Expert Commentary | Abstract | Slides
Secondary prophylaxis of hepatic encephalopathy: An open-label randomized controlled trial of lactulose versus placebo.
Sharma BC, Sharma P, Agrawal A, Sarin SK. Gastroenterology. 2009;137:885-891. Capsule Summary | Expert Commentary | Abstract | Slides
Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time.
Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Hepatology. 2009;49:1859-1867. Capsule Summary | Expert Commentary | Abstract | Slides
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Everhart JE, Lok AS, Kim HY, et al. Gastroenterology. 2009;137:549-557. Capsule Summary | Expert Commentary | Abstract | Slides
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection.
McHutchison JG, Everson GT, Gordon SC, et al. New Engl J Med. 2009;360:1827-1838. Capsule Summary | Expert Commentary | Abstract | Slides
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon BR, Shiffman ML, Mendes F, et al. Hepatology. 2009;49:1838-1846. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Volume 3, Issue 3
Collection
Hepatitis Journal Options – Volume 3, Issue 3
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
  
- Natalie H. Bzowej, MD, PhD
- Peter Ferenci, MD
- Michael Gale, Jr., PhD
|
  
- Stuart C. Gordon, MD
- Tarek Hassanein, MD, FACP, FACG, AGAF
- Paul Y. Kwo, MD
|
 
- Alessandra Mangia, MD
- Sammy Saab, MD, MPH, AGAF
|
Volume 3, Issue 2
Collection
Hepatitis Journal Options – Volume 3, Issue 2
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
 
- Jasmohan Bajaj, MD, MSc
- Wissam Bleibel, MD
- Steven Flamm, MD
|
  
- Ira M. Jacobson, MD
- Daryl T-Y Lau, MD, MSc, MPH
- Kevin Mullen, MD
|
  
- David R. Nelson, MD
- Nancy Reau, MD
- Richard K. Sterling, MD, MSc, FACP, FACG
|
 |
|